HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results
David A. Braun(Yale University), David Sommerhalder(Texas Oncology), Ryan H. Moy(Columbia University Irving Medical Center), Toni K. Choueiri(Harvard University), Anita Scheuber(Nimbus (Italy)), Sritama Nath(University of North Carolina at Charlotte), Kurt Demel(Immunovaccine (Canada)), Julio Peguero(Hematology Oncology Consultants), Rama Balaraman(Cardiovascular Institute of Central Florida), Scott R. Daigle(Epizyme (United States)), Marcus S. Noel(Georgetown University), Shirish Gadgeel(Henry Ford Health System), Martin Gutierrez(Hackensack University Medical Center), Dr. Sunil Kumar Sharma(HonorHealth), Pavan Kumar, Brian Van Tine(Washington University in St. Louis), GiNell Elliott(Boston Biomedical Research Institute), Arif Hussain(University of Maryland, Baltimore), Hamid Emamekhoo(University of Wisconsin Carbone Cancer Center)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k